New drug SHR-A1811 tested in 1,000 lung cancer patients in Real-World setting
NCT ID NCT07516015
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how safe and effective the drug SHR-A1811 is for Chinese patients with advanced or spreading non-small cell lung cancer that has a specific genetic change called HER2 alteration. About 1,000 adults will be followed as they receive the drug as part of their normal care. The goal is to see side effects and how long the cancer stays under control.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep lung cancer from returning after surgery?
- Aiming to spare lung cancer patients from chemo: a smarter Pre-Surgery plan?
- Can a Two-Target antibody shrink Hard-to-Treat cancers?
- Can extended poziotinib use keep cancer in check?
- Can zapping tumors before surgery boost lung cancer treatment?
- Can a Two-Pronged antibody boost Chemo's power against lung cancer?